Phenotypes associated with this allele

• Allele Symbol: Setd4^{tm1c(KOMP)Wtsi}
• Allele Name: targeted mutation 1c, Wellcome Trust Sanger Institute
• Allele ID: MGI:6505434
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Setd4^tm1c(KOMP)Wtsi/Setd4^tm1c(KOMP)Wtsi Trp53^tm1Brn/Trp53^tm1Brn Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N	MGI:6695303
cn2	Setd4^tm1c(KOMP)Wtsi/Setd4^tm1c(KOMP)Wtsi Trp53^tm1Brn/Trp53^+ Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N	MGI:6695305
cn3	Setd4^tm1c(KOMP)Wtsi/Setd4^tm1c(KOMP)Wtsi Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj/Gt(ROSA)26Sor^+	involves: 129S4/SvJae * C57BL/6 * C57BL/6N	MGI:6695300

Genotype
MGI:6695303

cn1

• Allelic Composition: Setd4^{tm1c(KOMP)Wtsi}/Setd4^{tm1c(KOMP)Wtsi}; Trp53^tm1Brn/Trp53^tm1Brn; Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N
• Cell Lines: EPD0225_5_D10

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased mortality induced by gamma-irradiation ( J:297725 )

• after exposure to 4 weekly 2 Gy of total body gamma-irradiation, most tamoxifen-treated adult mice die within 100 days post irradiation

neoplasm

decreased metastatic potential ( J:297725 )

• gamma-irradiated tamoxifen-treated mice die mainly of non-disseminated thymic lymphomas, unlike mice that are homozygous for Setd4^{tm1c(KOMP)Wtsi}and heterozygous for Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj} where tumors are widely disseminated to other organs

increased tumor growth/size ( J:297725 )

• in gamma-irradiated tamoxifen-treated mice, thymic lymphomas are significantly larger in size/weight relative to those in mice that are only homozygous for Setd4^{tm1c(KOMP)Wtsi}and heterozygous for Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}

abnormal tumor latency ( J:297725 )

• after exposure to 4 weekly 2 Gy of total body gamma-irradiation, tamoxifen-treated adult mice fail to display a delay in the development of radiation-induced thymic lymphomas

decreased tumor latency ( J:297725 )

• sham-irradiated, tamoxifen-treated double mutant mice show accelerated spontaneous tumor development relative to mice that are only homozygous for Trp53^tm1Brn and heterozygous for Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}

homeostasis/metabolism

increased mortality induced by gamma-irradiation ( J:297725 )

• after exposure to 4 weekly 2 Gy of total body gamma-irradiation, most tamoxifen-treated adult mice die within 100 days post irradiation

Genotype
MGI:6695305

cn2

• Allelic Composition: Setd4^{tm1c(KOMP)Wtsi}/Setd4^{tm1c(KOMP)Wtsi}; Trp53^tm1Brn/Trp53⁺; Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N
• Cell Lines: EPD0225_5_D10

neoplasm

neoplasm ( J:297725 )

N • sham-irradiated, tamoxifen-treated mice show no significant differences in spontaneous tumor development or survival relative to mice that are heterozygous for Trp53^tm1Brn and Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj} but wild-type for Setd4

abnormal tumor latency ( J:297725 )

• after exposure to 4 weekly 2 Gy of total body gamma-irradiation, tamoxifen-treated adult mice fail to display a delay in the development of radiation-induced thymic lymphomas

Genotype
MGI:6695300

cn3

• Allelic Composition: Setd4^{tm1c(KOMP)Wtsi}/Setd4^{tm1c(KOMP)Wtsi}; Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * C57BL/6N
• Cell Lines: EPD0225_5_D10

mortality/aging

decreased mortality induced by ionizing radiation ( J:297725 )

• after exposure to 4 weekly 2 Gy of total body gamma-irradiation, tamoxifen-treated adult mice show delayed thymic lymphoma-mediated death and improved overall survival with a median survival of 245 days versus 195 days in oil-treated controls; 500 days after irradiation, the lymphoma-free survival 22% versus 9.4% in oil-treated controls

• however, non-irradiated tamoxifen-treated adults show no significant differences in survival up to 700 days relative to oil-treated controls

neoplasm

abnormal tumor pathology ( J:297725 )

• after exposure to total body gamma-irradiation, tamoxifen-treated adult mice exhibit a lower % of cleaved caspase-3 positive cells in their lymphomas than oil-treated controls

• although radiation-induced T cell lymphomas are largely clonogenic, thymic lymphomas of tamoxifen-treated mice are composed mainly of CD4+ CD8+ double positive cells whereas tumors in oil-treated control mice are largely composed of CD8+ single positive cells

• radiation-induced thymic lymphomas of tamoxifen-treated mice exhibit more chromosomal inversions but fewer deletion events than control tumors

increased metastatic potential ( J:297725 )

• after exposure to total body gamma-irradiation, tamoxifen-treated adult mice show a more widespread infiltration of peripheral organs (spleen, liver, kidney, and lung) by T-lymphoma cells and a higher tumor dissemination score at the time of death relative to oil-treated controls

decreased tumor growth/size ( J:297725 )

• after exposure to total body gamma-irradiation, tamoxifen-treated adult mice that die within the first 195 days post-irradiation show a slight reduction in the size/weight of lymphomas relative to oil-treated controls

• however, no significant difference in primary thymus tumor weight is noted at the time of death

increased tumor latency ( J:297725 )

• after exposure to total body gamma-irradiation, tamoxifen-treated adult mice show a significant delay in the development of radiation-induced thymic lymphomas and lymphoma-mediated death relative to oil-treated controls, likely due to slower tumor enlargement in the thymus

• however, non-irradiated tamoxifen-treated adults show no obvious growth retardation or tumor development up to 700 days relative to oil-treated controls

homeostasis/metabolism

decreased mortality induced by ionizing radiation ( J:297725 )

• after exposure to 4 weekly 2 Gy of total body gamma-irradiation, tamoxifen-treated adult mice show delayed thymic lymphoma-mediated death and improved overall survival with a median survival of 245 days versus 195 days in oil-treated controls; 500 days after irradiation, the lymphoma-free survival 22% versus 9.4% in oil-treated controls

• however, non-irradiated tamoxifen-treated adults show no significant differences in survival up to 700 days relative to oil-treated controls

cellular

decreased apoptosis ( J:297725 )

• after exposure to total body gamma-irradiation, tamoxifen-treated adult mice exhibit a lower percentage of cleaved caspase-3 positive cells in their lymphomas than oil-treated controls